Health Care & Life Sciences » Pharmaceuticals | Amarillo Biosciences Inc.

Amarillo Biosciences Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
6.50
318.60
21.10
134.10
1,980.00
1,276.70
Inventories
0.20
-
-
14.70
22.70
-
Other Current Assets
61.80
16.90
18.20
113.60
81.80
26.60
Total Current Assets
68.50
335.40
39.30
262.40
2,084.50
1,303.20
Net Property, Plant & Equipment
-
-
5.80
44.20
27.00
14
Intangible Assets
93.00
86.10
72.10
156.10
182.40
146.50
Total Assets
161.50
421.50
117.20
462.70
2,293.80
1,463.70
ST Debt & Current Portion LT Debt
3,545.40
234.60
384.60
791.50
886.50
Accounts Payable
269.90
67.20
-
165.50
159.30
Other Current Liabilities
1,129.00
0.60
204.70
315.60
777.30
Total Current Liabilities
4,944.30
302.30
589.20
1,272.60
1,823.00
Long-Term Debt
-
150.00
-
-
-
Total Liabilities
4,944.30
452.30
589.20
1,272.60
1,823.00
Common Equity (Total)
4,782.80
30.70
472.00
809.90
470.80
Total Shareholders' Equity
4,782.80
30.70
472.00
809.90
470.80
Total Equity
4,782.80
30.70
472.00
809.90
470.80
Liabilities & Shareholders' Equity
161.50
421.50
117.20
462.70
2,293.80
Preferred Stock (Carrying Value)
0.00
-
-
-
-

About Amarillo Biosciences

View Profile
Address
4134 Business Park Drive
Amarillo Texas 79110
United States
Employees -
Website http://www.amarbio.com
Updated 07/08/2019
Amarillo Biosciences, Inc. engages in developing biologics for the treatment of human and animal diseases. It focuses on research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. The company was founded by Joseph M.